Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes

Jianfeng Xu, Deborah A. Meyers, David Sterling, Siqun L. Zheng, William J. Catalona, Scott D. Cramer, Eugene R. Bleecker, Jill Ohar

Research output: Contribution to journalArticleResearchpeer-review

42 Citations (Scopus)

Abstract

Testing for serum prostate-specific antigen (PSA) levels has been widely used to screen for prostate cancer. However, PSA testing has low specificity and sensitivity because PSA is not prostate cancer-specific. PSA is encoded by the APS gene, and the expression of this gene is regulated by androgens. W. Xue et al. Cancer Res., 60: 839-841, 2000 reported recently that serum PSA levels are associated with a G/A polymorphism at androgen responsive element 1 (ARE1) of APS and/or the CAG repeats in exon 1 of the androgen receptor (AR) gene. This result, if confirmed, may significantly increase the specificity and sensitivity of PSA testing by incorporating genotype-specific thresholds. In this study, we tested for the association between serum PSA levels and these single nucleotide polymorphisms (SNPs) in a large sample of 518 men. For the AR gene, we observed slightly (but not statistically significant) higher mean serum PSA levels in men with shorter CAG repeats (≤21) or shorter GGC repeats (≤16). For the ARE1 of the APS, we found slightly (but not statistically significant) lower PSA levels in men with the AA genotype. It is worth noting that this observation is opposite to the findings of W. Xue et al. Cancer Res., 60: 839-841, 2000. We hypothesize that the effects of ARE1 and AR genotypes on mean PSA levels may reflect the effect of other causal polymorphisms in these genes, which are in linkage disequilibrium with these polymorphisms. A systematic approach is required to identify sequence variants in these genes and other related genes, and to test for an association between these variants and PSA levels in large samples. ɫ 2002 American Association for Cancer Research.

Original languageEnglish
Pages (from-to)664-669
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume11
Issue number7
StatePublished - 1 Jan 2002

Fingerprint

Androgen Receptors
Genetic Polymorphisms
Prostate-Specific Antigen
Serum
Genes
Androgens
Genotype
Prostatic Neoplasms
Sensitivity and Specificity
Linkage Disequilibrium
Single Nucleotide Polymorphism
Exons
Neoplasms
Gene Expression

Cite this

Xu, Jianfeng ; Meyers, Deborah A. ; Sterling, David ; Zheng, Siqun L. ; Catalona, William J. ; Cramer, Scott D. ; Bleecker, Eugene R. ; Ohar, Jill. / Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. In: Cancer Epidemiology Biomarkers and Prevention. 2002 ; Vol. 11, No. 7. pp. 664-669.
@article{7d75fbeeb75a42609563222e41171826,
title = "Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes",
abstract = "Testing for serum prostate-specific antigen (PSA) levels has been widely used to screen for prostate cancer. However, PSA testing has low specificity and sensitivity because PSA is not prostate cancer-specific. PSA is encoded by the APS gene, and the expression of this gene is regulated by androgens. W. Xue et al. Cancer Res., 60: 839-841, 2000 reported recently that serum PSA levels are associated with a G/A polymorphism at androgen responsive element 1 (ARE1) of APS and/or the CAG repeats in exon 1 of the androgen receptor (AR) gene. This result, if confirmed, may significantly increase the specificity and sensitivity of PSA testing by incorporating genotype-specific thresholds. In this study, we tested for the association between serum PSA levels and these single nucleotide polymorphisms (SNPs) in a large sample of 518 men. For the AR gene, we observed slightly (but not statistically significant) higher mean serum PSA levels in men with shorter CAG repeats (≤21) or shorter GGC repeats (≤16). For the ARE1 of the APS, we found slightly (but not statistically significant) lower PSA levels in men with the AA genotype. It is worth noting that this observation is opposite to the findings of W. Xue et al. Cancer Res., 60: 839-841, 2000. We hypothesize that the effects of ARE1 and AR genotypes on mean PSA levels may reflect the effect of other causal polymorphisms in these genes, which are in linkage disequilibrium with these polymorphisms. A systematic approach is required to identify sequence variants in these genes and other related genes, and to test for an association between these variants and PSA levels in large samples. ɫ 2002 American Association for Cancer Research.",
author = "Jianfeng Xu and Meyers, {Deborah A.} and David Sterling and Zheng, {Siqun L.} and Catalona, {William J.} and Cramer, {Scott D.} and Bleecker, {Eugene R.} and Jill Ohar",
year = "2002",
month = "1",
day = "1",
language = "English",
volume = "11",
pages = "664--669",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. / Xu, Jianfeng; Meyers, Deborah A.; Sterling, David; Zheng, Siqun L.; Catalona, William J.; Cramer, Scott D.; Bleecker, Eugene R.; Ohar, Jill.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 11, No. 7, 01.01.2002, p. 664-669.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes

AU - Xu, Jianfeng

AU - Meyers, Deborah A.

AU - Sterling, David

AU - Zheng, Siqun L.

AU - Catalona, William J.

AU - Cramer, Scott D.

AU - Bleecker, Eugene R.

AU - Ohar, Jill

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Testing for serum prostate-specific antigen (PSA) levels has been widely used to screen for prostate cancer. However, PSA testing has low specificity and sensitivity because PSA is not prostate cancer-specific. PSA is encoded by the APS gene, and the expression of this gene is regulated by androgens. W. Xue et al. Cancer Res., 60: 839-841, 2000 reported recently that serum PSA levels are associated with a G/A polymorphism at androgen responsive element 1 (ARE1) of APS and/or the CAG repeats in exon 1 of the androgen receptor (AR) gene. This result, if confirmed, may significantly increase the specificity and sensitivity of PSA testing by incorporating genotype-specific thresholds. In this study, we tested for the association between serum PSA levels and these single nucleotide polymorphisms (SNPs) in a large sample of 518 men. For the AR gene, we observed slightly (but not statistically significant) higher mean serum PSA levels in men with shorter CAG repeats (≤21) or shorter GGC repeats (≤16). For the ARE1 of the APS, we found slightly (but not statistically significant) lower PSA levels in men with the AA genotype. It is worth noting that this observation is opposite to the findings of W. Xue et al. Cancer Res., 60: 839-841, 2000. We hypothesize that the effects of ARE1 and AR genotypes on mean PSA levels may reflect the effect of other causal polymorphisms in these genes, which are in linkage disequilibrium with these polymorphisms. A systematic approach is required to identify sequence variants in these genes and other related genes, and to test for an association between these variants and PSA levels in large samples. ɫ 2002 American Association for Cancer Research.

AB - Testing for serum prostate-specific antigen (PSA) levels has been widely used to screen for prostate cancer. However, PSA testing has low specificity and sensitivity because PSA is not prostate cancer-specific. PSA is encoded by the APS gene, and the expression of this gene is regulated by androgens. W. Xue et al. Cancer Res., 60: 839-841, 2000 reported recently that serum PSA levels are associated with a G/A polymorphism at androgen responsive element 1 (ARE1) of APS and/or the CAG repeats in exon 1 of the androgen receptor (AR) gene. This result, if confirmed, may significantly increase the specificity and sensitivity of PSA testing by incorporating genotype-specific thresholds. In this study, we tested for the association between serum PSA levels and these single nucleotide polymorphisms (SNPs) in a large sample of 518 men. For the AR gene, we observed slightly (but not statistically significant) higher mean serum PSA levels in men with shorter CAG repeats (≤21) or shorter GGC repeats (≤16). For the ARE1 of the APS, we found slightly (but not statistically significant) lower PSA levels in men with the AA genotype. It is worth noting that this observation is opposite to the findings of W. Xue et al. Cancer Res., 60: 839-841, 2000. We hypothesize that the effects of ARE1 and AR genotypes on mean PSA levels may reflect the effect of other causal polymorphisms in these genes, which are in linkage disequilibrium with these polymorphisms. A systematic approach is required to identify sequence variants in these genes and other related genes, and to test for an association between these variants and PSA levels in large samples. ɫ 2002 American Association for Cancer Research.

UR - http://www.scopus.com/inward/record.url?scp=0036313591&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 664

EP - 669

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -